Human albumin infusions, frequently administered alongside antibiotics to patients suffering from liver cirrhosis and bacterial infections, yield highly uncertain clinical outcomes. According to a comprehensive evaluation, researchers remain deeply unclear on whether albumin reduces mortality, prevents kidney damage, or alters rates of serious complications compared to no intervention or alternative intravenous fluids.
In Plain English: The Clinical Takeaway
- What albumin is: A blood protein that assists in regulating fluid levels within the circulatory system, which is the network responsible for moving blood through vessels throughout the body.
- The core uncertainty: Current clinical trials are too flawed to prove whether giving albumin alongside antibiotics actually saves lives or stops kidney damage in infected cirrhosis patients.
- The evidence gap: Researchers evaluated 1,273 adults across 11 studies, but design flaws and insufficient data mean medical consensus cannot yet endorse routine albumin use for these specific infection complications.
Clinical Trials Reveal Persistent Uncertainty in Cirrhosis Care
Cirrhosis is scarring of the liver, which develops over time. Patients with advanced liver damage frequently develop severe bacterial infections, including spontaneous bacterial peritonitis—an infection of the peritoneum membrane lining the inside of the tummy. To assess the benefits and risks of human albumin in addition to antibiotics, researchers analyzed 11 clinical trials encompassing 1,273 adult participants with an average age of 54 years.
Every participant across these investigations received antibiotics. However, the trials divided the interventions: eight studies compared albumin against no treatment, while three studies evaluated albumin against different types of intravenous fluids. Five of the trials focused specifically on spontaneous bacterial peritonitis, four examined infections across various body parts like the lungs, urinary tract, and skin, and two observed patients suffering from dangerously low blood pressure due to a severe infection.
Despite examining outcomes across clinical centers in India, Spain, China, France, Egypt, and Taiwan, investigators identified problems in the way the studies were performed. These methodological limitations reduced the certainty of the findings. Consequently, evidence regarding whether albumin affects death due to any cause, limits serious unwanted events, or prevents septic shock remains very uncertain.
| Comparison Group | Number of Studies | Participant Count | Primary Evaluated Outcomes | Certainty of Evidence |
|---|---|---|---|---|
| Albumin vs. No Intervention | 8 studies | Variable (Subset of 1,273 total) | All-cause mortality, kidney damage, septic shock | Very Low / Uncertain |
| Albumin vs. Other Intravenous Fluids | 3 studies | Variable (Subset of 1,273 total) | Mortality, adverse events, kidney protection | Very Low / Uncertain |
Evaluating Alternative Intravenous Fluids and Infection Sites
The comparative analysis between human albumin and alternative intravenous fluids yielded similarly inconclusive results. Researchers attempted to determine if other intravenous fluids offered comparable efficacy to albumin when managing fluid volume. The data showed extreme uncertainty surrounding whether albumin offers any tangible advantage in reducing kidney impairment or preventing septic shock when set against these alternative intravenous fluids.
Furthermore, for both comparisons, researchers could not assess the effect of albumin regarding the site of infection. Whether a patient presented with a pulmonary infection, a urinary tract pathogen, or peritoneal contamination, the available data subsets proved insufficient for a meaningful subgroup analysis. None of the included studies reported data on well-being.
Ten of the analyzed trials were either free from for-profit support or did not report the sources of support, while a single trial declared partial private support, delivering albumin vials. Because methodological rigor varied widely and sample sizes remained modest—particularly given the absence of children—it cannot be established whether albumin is superior to conventional fluid management in infected cirrhosis cases.
When to Consult a Doctor
People with liver cirrhosis are prone to bacterial infections. Health issues stemming from cirrhosis may manifest as abdominal fluid buildup, cognitive decline, or jaundice. If treated on time, complications and death can be reduced.
Future Research Pathways and Evidence Timelines
Closing the clinical knowledge gap requires more larger studies where the people and investigators are not aware of the treatments being used. Future investigations must also incorporate children and directly compare differences in the albumin used and compare it with other types of intravenous fluids. The current evidentiary database remains current through 20 August 2025.
References
- Cochrane Database of Systematic Reviews – Human albumin for people with cirrhosis of the liver and bacterial infection.
